Hereditary spherocytosis is a genetically determined disease characterized by a change in the shape of red blood cells - blood cells responsible for oxygen transport. Normally, red blood cells have a biplanar disc-shaped form, which ensures their flexibility and the ability to move freely through the capillaries. With spherocytosis, this shape changes to a rounded one, which leads to a decrease in the mechanical strength of the cells and their premature destruction in the spleen. This condition often manifests itself as anemia, jaundice, and an enlarged liver and spleen. The disease is hereditary and can manifest itself in varying degrees of severity in both children and adults.
History of the disease and interesting historical facts
The first mention of hereditary spherocytosis dates back to the early 20th century, when scientists described the characteristic signs of the disease. However, more extensive research began only in the 1950s, when the genetic and biochemical mechanisms associated with the pathology were established. An interesting fact is that hereditary spherocytosis was one of the first diseases for which a genetic component was established, linking a change in hemolysis with a mutation in specific genes. Studies conducted in the 1960s and 1970s confirmed that spherocytosis is often associated with a mutation in genes encoding structural proteins of the cell membrane.
Epidemiology
Today, it is known that hereditary spherocytosis is one of the most common hereditary diseases of the hematopoietic system. Its frequency among the population is approximately 1 in 2,000–3,000 people. Prevalence varies depending on ethnicity and geographic location. For example, among people of European descent, the disease occurs significantly more often than among representatives of African or Asian peoples. According to various epidemiological studies, hereditary spherocytosis is more common in people with a family history of the disease, which emphasizes its hereditary nature.
Genetic predisposition to this disease
The main gene involved in the development of hereditary spherocytosis is the ANK1 gene, which codes for the protein ankyrin-1. Mutations in this gene lead to instability of the red blood cell membrane and, as a result, to the formation of spheroid cells. However, other genes are also involved, such as SPTB (encodes beta-spectrin) and EPB42 (encodes a protein involved in the connection of the membrane with the cytoskeleton). These mutations can vary in type and number, creating a wide spectrum of clinical manifestations of the disease. In most cases, hereditary spherocytosis is transmitted in an autosomal dominant manner, which means that one allele is enough to manifest symptoms of the disease.
Risk factors for the development of this disease
Risk factors for hereditary spherocytosis are primarily related to genetic predisposition, but certain external influences may also be considered. These include:
- Having a family history of spherocytosis or other forms of anemia.
- Existing pathologies compatible with abnormalities in the blood cell formula.
- Exposure to certain chemicals that may interfere with hematopoietic functions.
- Some infectious diseases can worsen the condition of hematopoiesis.
It is important to note that not all individuals with a predisposition to the disease will have clinical manifestations, as full manifestation often depends on a variety of factors, both genetic and environmental.
Diagnosis of this disease
Diagnosis of hereditary spherocytosis is based on clinical symptoms and laboratory tests. The main symptoms that may indicate this disease include:
- Chronic anemia.
- Jaundice.
- Enlargement of the liver and spleen.
- Decreased physical activity and fatigue.
Laboratory tests may include:
- A complete blood count to determine hemoglobin levels and red blood cell count.
- Determination of bilirubin levels and lactate dehydrogenase activity.
- Examination of a blood smear to detect spherocytes.
Radiological examination may be necessary to assess the size of the spleen and liver. In some cases, splenectomy may also be performed to improve the patient's condition. Differential diagnosis includes separating spherocytosis from other forms of hemolytic anemia.
Treatment
Treatment of hereditary spherocytosis depends largely on the severity of clinical symptoms and the patient's overall condition. General treatment approaches may include:
- Supportive therapy: administration of folic acid to ensure normal hematopoiesis.
- Pharmacological treatment: drugs aimed at improving the state of hemoglobin, for example, iron-containing drugs.
- Surgical treatment: splenectomy, which may be recommended in cases of severe and persistent anemia associated with hemolysis.
- Other therapies such as blood transfusion in acute cases.
The result of effective treatment is usually an improvement in the general condition of the patient and a reduction in the frequency of hemolytic episodes.
List of medications used to treat this disease
The main drugs used in the treatment of hereditary spherocytosis include:
- Folic acid
- Iron preparations (for example, Ferrum Lek)
- Corticosteroids (in rare cases with severe hemolysis)
- Hydroxyurea (in some severe cases)
These drugs help maintain hemoglobin levels and prevent further deterioration of the condition.
Disease monitoring
Monitoring of the patient with hereditary spherocytosis includes regular check-ups aimed at assessing the hemoglobin level, liver and spleen condition, and the frequency of hemolytic crises. The prognosis of the disease largely depends on the timely initiation of treatment and correction of the condition. Complications may include splenomegaly, hemolytic anemia, and the risk of thrombosis, so regular medical examinations are mandatory.
Age-related features of the disease
Hereditary spherocytosis may present at any age, but the highest frequency of clinical symptoms occurs in childhood. In infants and young children, the disease may be more severe and lead to severe forms of anemia. In adult patients, the clinical course may be more variable, with less severe anemia and frequent compensatory mechanisms. In addition, older patients are at risk for more serious complications, such as thrombosis.
Questions and Answers
- What are the main causes of hereditary spherocytosis? Mutations in genes encoding proteins responsible for the structure and stability of the red blood cell membrane.
- How is hereditary spherocytosis treated? Treatment may include supportive care, medications, and surgery to remove the spleen in severe cases.
- What are the symptoms of hereditary spherocytosis? Symptoms include chronic anemia, jaundice, enlarged liver and spleen, as well as fatigue and decreased physical activity.
- How is spherocytosis inherited? The disease is usually transmitted in an autosomal dominant manner, meaning that one mutant allele is enough to cause symptoms.
- What are the consequences of hereditary spherocytosis? Complications such as hepatosplenomegaly, development of thrombus formation or other hemolytic episodes are possible.
In conclusion, Dr. Oleg Korzhikov recommends always paying attention to symptoms that may indicate hereditary spherocytosis, especially in cases with a predisposition in the family. Regular examinations and support from professionals will not only help to avoid complications, but also improve the quality of life of patients. Remember that competent diagnostics and therapy are the key to successful disease management, and following the doctor's recommendations will ensure the most effective treatment and maintenance of overall health.
